Luye Pharma Group Ltd.

LYPHFOTCHealthcare● Active

$0.20

+$0.00(+0.00%)

Market Cap$815280706

P/E Ratio—

52W High$0.395

52W Low$0.2041

Avg Volume65K

Open$0.37

Beta0.86

Free Cash Flow Financials Revenue

Luye Pharma Group Ltd. (LYPHF) Free Cash Flow & Analysis

Annual & trailing free cash flow, FCF margin, YoY change, valuation ratios, and peer context.

LYPHF · free cash flow · updated Jun 15, 2026

Core FCF metrics

LYPHF · FCF · TTM · margin & CAGR

Free cash flow was $780.4M for FY2025 (fiscal year ending 2025-12-31), up 150.7% year-over-year The FCF margin was 12.7%.

FY2025 Free Cash Flow$780.4M▲ +150.7% YoY

Trailing 12M (TTM)$655.9Mtrailing 4 quarters sum

FCF Margin12.7%$780.4M ÷ revenue

3-Year CAGR+16.8%FY2022 → FY2025

5-Year CAGRN/AN/A — contains negative FCF

FormulaFCF = Operating Cash Flow − Capital ExpendituresTTM = trailing 4 quarters sumCAGR → N/A if either endpoint ≤ 0

Source: FMP /cash-flow-statement · SEC 10-K / 10-Q · USDUpdated: Jun 15, 2026

Annual free cash flow history

FCF ($B, upper) · YoY Growth % (lower)

Positive FCFNegative FCF

Free Cash Flow

YoY Growth %

Annual free cash flow data

LYPHF · free cash flow history · annual / quarterly

Fiscal YearOperating CFCapExFree Cash FlowYoY ChangeFCF Margin

FY2025Latest$1.78B(1.00B)$780.4M▲ +150.7%12.7%

FY2024$167.8M(1.71B)−$1.54B▼ 458.1%-25.4%

FY2023$1.60B(1.17B)$430.2M▼ 12.2%7.0%

FY2022$1.65B(1.16B)$490.1M▲ +136.1%8.2%

FY2021$182.4M(1.54B)−$1.36B▼ 179.4%-26.1%

FCF = Operating Cash Flow − Capital Expenditures · CapEx shown as (negative) · Source: SEC filings via FMP

FCF valuation metrics

LYPHF · P/FCF · FCF yield · FCF per share

Luye Pharma Group Ltd. (LYPHF) trades at a FCF yield of 24.25% and a price-to-free-cash-flow ratio of 1.2x. FCF per share stands at $0.17, calculated using trailing twelve-month FCF divided by basic weighted-average shares outstanding.

FCF Yield (TTM)

24.25%

Free Cash Flow ÷ Market Cap

per FMP freeCashFlowYieldTTM definition

FCF per Share (TTM)

$0.17

TTM FCF ÷ Shares Outstanding

Price / FCF

x1.2

Share Price ÷ FCF per Share

EV / FCF (TTM)

x7.3

Enterprise Value basis

Source: FMP /key-metrics-ttm · /cash-flow-statement Q · /income-statementFY2025 · 2025-12-31

Cash flow statement summary

LYPHF · cash flow statement · operating / investing / financing

For FY2025, Luye Pharma Group Ltd. generated $1.78B in operating cash flow and spent 1.00B in capital expenditures, yielding $780.4M in free cash flow.

Operating Activities

+$1.78B

Cash from core business operations

2025-12-31

Investing Activities

−$3.99B

CapEx, acquisitions & investments

2025-12-31

Financing Activities

+$1.79B

Buybacks, dividends & debt

2025-12-31

FCF FormulaOperating CF ($1.78B) − |CapEx| (1.00B) = FCF ($780.4M)

For the complete Operating / Investing / Financing line-item breakdown:

View Full Cash Flow Statement →

Free cash flow vs peers (Healthcare)

LYPHF vs peers · FCF

#CompanyFree Cash FlowYoYFCF MarginRelative

Luye Pharma Group Ltd.YOU

LYPHF

$780.4M+150.7%12.7%

UnitedHealth Group Incorporated

UNH

$16.07B-22.4%3.6%

82%

Eli Lilly and Company

LLY

$8.97B+2065.6%13.8%

46%

Healthcare · Sorted by FCF · FMP /cash-flow-statementFull FCF Rankings →

About Free Cash Flow & Methodology

Luye Pharma Group Ltd. (LYPHF) reported free cash flow of $780.4M for FY2025 (fiscal year ending 2025-12-31), up 150.7% year-over-year. The FCF margin was 12.7%.

Based on available data, Luye Pharma Group Ltd. has maintained positive free cash flow for at least 9 fiscal year(s). FCF peaked at $780.4M in FY2025.

Luye Pharma Group Ltd.'s FCF yield is 24.25% and price-to-FCF ratio is 1.2x for FY2025, based on the latest available data.

Data sourced from FMP /cash-flow-statement · SEC 10-K / 10-Q · USD.

Q&A and summaries align with SEC 10-K/10-Q cash flow disclosures and FMP /cash-flow-statement where noted.

Revenue Financial statements Net income Earnings Forecast Price history Market cap Cash on hand P/E ratio

Frequently asked questions

LYPHF free cash flow · 8 questions

Luye Pharma Group Ltd. free cash flow was $780.4M for FY2025, up 150.7% year-over-year. On a trailing twelve-month (TTM) basis, free cash flow stands at $655.9M.

LYPHF free cash flowLYPHF FCFLYPHF FCF 2025LYPHF free cash flow TTM

▸ Source: FMP /cash-flow-statement · US GAAP · Luye Pharma Group Ltd. · Luye Pharma Group Ltd. SEC 10-K & 10-Q filings · US GAAP · Last updated: Jun 15, 2026